Business
GBX International Group, Inc. (OTC:GBXI) Confirms 2023 Strong Revenue Growth Guidance Projections by Combining Each Acquired Operating Company Product Release, Expects Strong Growth Sector by Sector Through its Multiple Product Releases into North America
GBX International Group, Inc. (OTC:GBXI) Confirms 2023 Strong Revenue Growth Guidance Projections by Combining Each Acquired Operating Company Product Release, Expects Strong Growth Sector by Sector Through its Multiple Product Releases into North America.
About this update from Gbx International Group Inc.
[{"type":"text","content":"LOS ANGELES, CA / ACCESSWIRE / May 11, 2023 / GBX International Group, Inc., (OTC:GBXI) an emerging leader in international economic development, is pleased to confirm its 2023 projected revenue growth reports. GBXI forecasts its business combinations to fuel strong revenue growth quarter by quarter and year over year. This is simply based on releasing the wide range of completed products and services from the respective Companies acquired and its targeted industry sector. Putting these revenues on the books of GBXI is the key to significantly increased shareholder value and increased market capitalization.The GBXI's strong 2023 revenue growth guidance is projected to be well over several million in revenues when you combine the projected revenues for each company under the new GBXI umbrella of Companies. Below you will find the itemized revenue growth guidance tables that paint a much stronger picture of the immediate and sustained revenue growth. GBXI has put itself in a very strong position to capitalize and dramatically increase its shareholder value from the last (4) four acquisitions and their respective product lines being released over the coming quarters.GBXI will separate each acquired company product line and assign them to enrolled American States University student groups for their business acumen and experience with real world products and services. This is all centered through its newly acquired American States University Digital Business HUB student scholarship and apprenticeship programs.1. Cannabis Science Inc. (CSi-EDP)HARVARD Award Winning Cancer Killing Drug Development. Our Top CSi-Drug Valuation targets are ready for Pharmacokinetics and FDA IND# application:Stage 4 Lung CancerPancreatic CancerStage 4 Breast CancerBasil Cell Carcinoma (Skin CancerThe Company has found a viable FDA drug development partner. The Company is now finalizing the terms to begin the FDA IND # process to commercialize its cancer drugs in the USA and Europe. This tremendous Success is for "Just one Cancer Drug". Most Successful drug companies have 10 - 25 drug targets or more.The Lung Cancer Market: $15,404,467,199.85. EACH YEAR, Worldwide, $15 Billion.We have at least four or five Cancer Targets ready. Two are ready for FDA IND # packaging and launch.Most Companies do not go into business unless they think they can attain...